Cannara Biotech Inc. (LOVE) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Canara Biotech's fiscal year Q3 financial results for the three and nine months ended May 31st, 2025. As a reminder, this presentation is being recorded. Following prepared remarks, we will conduct a question and answer session. Please submit your questions to investors at canara.ca or in the chat option in your browser. Before we begin, please refer to slide two and three of our earnings presentation. All information today It's subject to our general disclaimers on financial measures and forward-looking statements, which are available to be read in detail at cedarplus.ca. I will now turn the presentation over to Nicholas Sosiat, Chief Financial Officer at Canara Biotech. Thank you, Scott. Good morning, everyone, and thank you for joining Canara's earning presentation for the fiscal third quarter, ended May 31st, 2025. My name is Nicholas Sosiak, CFO of Canara, and as many of you may know, I have been deeply involved in every aspect of this company since 2019. From cultivation to processing, finance, strategy, construction, sales and marketing, product development, you name it, I've had my hands in it. Today, it will be my pleasure to provide you with an update on our best quarter since the company's inception, our third quarter ending May 31, 2025. I am proud to announce that we are executing to plan steady quarter-over-quarter growth with Fisca Q3 2025 representing our strongest quarter yet, both operationally and financially. Operationally, we have achieved three very significant milestones for the business. First, we have completed our 2025 expansion strategy, turning online rooms 11 and 12 at our flagship Valleyfield facility. These new rooms will increase our annual capacity by 6,000 kg, increasing our original planned total annual c...